查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1964130

幽门螺旋桿菌诊断市场－全球产业规模、份额、趋势、机会、预测：按类型、技术、最终用户、地区和竞争格局划分，2021-2031年

Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Technology, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球幽门螺旋桿菌诊断市场预计将从 2025 年的 6.0578 亿美元成长到 2031 年的 7.8032 亿美元，复合年增长率为 4.31%。

该领域涵盖了用于检测胃黏膜细菌定植的侵入性和非侵入性诊断工具，例如尿素呼吸检测、粪便抗原切片检查。市场成长的主要驱动因素是全球消化性溃疡的高发病率以及透过早期识别病原体来降低胃癌风险的紧迫性。根据美国胃肠病学会2024年报告，北美幽门螺旋桿菌感染率仍然很高，在30%至40%之间波动，凸显了临床上对准确诊断干预措施的持续需求。

市场概览
预测期 2027-2031
市场规模：2025年 6.0578亿美元
市场规模：2031年 780,320,000 美元
复合年增长率：2026-2031年 4.31%
成长最快的细分市场 免疫检测
最大的市场 北美洲

市场扩张的主要障碍之一是开发中国家实施高精度检测所面临的经济和物流难题。儘管这些地区承受着最沉重的感染负担，但先进的非侵入性诊断技术高成本，且检查室基础设施不足，往往阻碍了广泛的筛检和监测活动。这种可及性差距限制了资源匮乏地区的市场渗透率，并限制了整体收入潜力，儘管患者群体庞大。

市场驱动因素

幽门螺旋桿菌相关性消化性溃疡和胃癌发生率的上升是推动市场成长的主要动力。由于这种病原体是非幽门胃癌最强的特异性危险因素，临床指引越来越强调根除治疗，而根除治疗高度依赖准确的早期诊断来预防恶性进展。长期感染与肿瘤之间的这种直接关联正在推动筛检的增加，尤其是在优先考虑早期疗育的高风险地区。 2024年2月，国际癌症研究机构（IARC）强调了这一情况的紧迫性，指出2022年全球报告了约97万例新发胃癌病例，并重申了早期细菌检测对于降低肿瘤风险的重要性。

同时，由于人们的偏好从侵入性切片检查显着转向呼吸检测和粪便抗原检测，诊断格局正在转变。医疗系统和患者越来越多地选择非侵入性检测方法，因为与内视镜检查相比，这些方法具有成本更低、更便捷、操作更舒适等优势。这一趋势在主要诊断设备製造商的财务表现中得到了清晰的体现。例如，大冢控股株式会社在2024年2月报告称，其2023财年医疗设备部门的销售额达到156.4亿日元，其中大部分来自尿素呼吸检测系统。此外，Fasom Pharmaceuticals公司估计，光是2024年美国就有1.15亿人感染，这代表着诊断应用领域一个非常巨大的潜在市场。

市场挑战

在开发中国家推广高精度检测有显着的经济和物流障碍，严重限制了全球幽门螺旋桿菌诊断市场的成长。儘管这些地区的细菌定植率最高，但非侵入性检测的高成本使得大规模筛检在经济上难以实现。这种价格差异实际上将很大一部分潜在患者群体排除在目标市场之外，因为在医疗资源匮乏的环境中，急性治疗优先于预防性监测。因此，诊断试剂生产商错失了在潜在需求最大的地区创造收入的机会。

此外，检查室基础设施的匮乏严重限制了精准检测方法的扩充性。许多诊断通讯协定需要专用设备，而资金不足的医疗中心往往难以获得这些设备，迫使它们依赖经验性治疗，从而延缓了最新技术的应用。考虑到持续存在的疾病负担，这种机会成本巨大。根据美国胃肠病学会2024年的报告，全球儿童和青少年幽门螺旋桿菌感染率仍高达35.1%。这项数据证实，由于物流障碍，现有市场策略无法触及的感染源依然存在。

市场趋势

在传统经验性治疗方法失败率不断上升的背景下，抗菌药物敏感性检测（AST）技术的广泛应用正在从根本上改变幽门螺旋桿菌的临床治疗方式。随着全球抗生素抗药性达到临界水平，医疗机构在开立处方前，优先考虑能够识别细菌抗药性谱（尤其是对克拉霉素和甲硝唑的抗药性）的诊断工具。这种从简单检测到详细药敏分析的转变对于避免无效治疗方法和合理管理抗生素使用至关重要。美国国立卫生研究院（NIH）2024年12月发布的报告显示，儿童对甲硝唑和克拉霉素的初始抗药性数据分别为35.3%和32.6%，凸显了市场对能够提供全面抗药性数据的诊断工具的迫切需求。

同时，人们对「个人化精准医疗诊断」的兴趣日益浓厚，这种诊断方式利用基因型资讯为每位患者制定最佳的根除策略。这一趋势正推动市场发展超越简单的阳性/阴性判定，并促进分子检测的应用，从而根据患者特定的细菌菌株指导选择最有效的一线治疗方案。透过将基因型抗药性检测整合到常规临床实践中，临床医师可以显着改善治疗效果，优于传统的试验误法。在2025年5月举行的消化疾病週（DDW）上，有报告指出，在将基因型抗药性检测作为第一线治疗指南后，根除成功率从77%（经验性治疗）提高到93%。这充分展现了精准诊断的临床和商业性价值。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球幽门螺旋桿菌诊断市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（设备、试剂、服务）
    • 依技术分类（免疫检测、即时检测、分子诊断）
    • 依最终使用者（医院/诊所、门诊中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美幽门螺旋桿菌诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲幽门螺旋桿菌诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区幽门螺旋桿菌诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲幽门螺旋桿菌诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美幽门螺旋桿菌诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球幽门螺旋桿菌诊断市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Thermo Fisher Scientific inc.
  • Biohit Oyj
  • Quest Diagnostics Incorporated
  • Meridian Bioscience
  • Bio-Rad Laboratories
  • Alpha Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Coris BioConcept
  • Certest Biotec
  • Epitope Diagnostics, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 21969

The Global Helicobacter Pylori Diagnostics Market is projected to expand from USD 605.78 Million in 2025 to USD 780.32 Million by 2031, registering a Compound Annual Growth Rate (CAGR) of 4.31%. This sector encompasses a range of invasive and non-invasive diagnostic tools, including urea breath tests, stool antigen assays, and endoscopic biopsies, which are essential for detecting bacterial colonization in the gastric mucosa. The primary catalyst for market growth is the high global prevalence of peptic ulcers and the urgent necessity to lower gastric cancer risks through early pathogen identification. As reported by the American College of Gastroenterology in 2024, Helicobacter pylori infection rates in North America remain significant, fluctuating between 30% and 40%, highlighting a sustained clinical requirement for accurate diagnostic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 605.78 Million
Market Size 2031USD 780.32 Million
CAGR 2026-20314.31%
Fastest Growing SegmentImmunoassays
Largest MarketNorth America

One major hurdle impeding market expansion is the economic and logistical difficulty of implementing high-precision testing in developing nations. Although these regions suffer the heaviest infection burdens, the high cost of advanced non-invasive diagnostics and inadequate laboratory infrastructure often preclude widespread screening and surveillance efforts. This gap in accessibility limits market penetration in resource-poor settings, thereby constraining the overall revenue potential despite the existence of a vast patient population.

Market Driver

The escalating incidence of H. pylori-associated peptic ulcers and gastric cancer acts as the primary engine for market growth. Since this pathogen is the strongest identifiable risk factor for non-cardia gastric cancer, clinical guidelines increasingly mandate eradication therapy, which relies heavily on accurate initial diagnosis to prevent malignancy. This direct correlation between long-term infection and oncology drives screening volumes, particularly in high-risk regions where early intervention is prioritized. The International Agency for Research on Cancer highlighted this urgency in February 2024, noting that stomach cancer accounted for approximately 970,000 new cases globally in 2022, underscoring the critical need for early bacterial detection to mitigate oncological risks.

Simultaneously, the diagnostic landscape is being transformed by a marked shift in preference from invasive biopsies to breath and stool antigen tests. Healthcare systems and patients increasingly favor non-invasive modalities due to their lower cost, ease of use, and reduced procedural discomfort compared to endoscopic methods. This trend is evident in the financial performance of major diagnostic manufacturers; for instance, Otsuka Holdings Co., Ltd. reported in February 2024 that its Medical Devices division generated 15,640 million yen in sales for fiscal 2023, largely driven by urea breath test systems. Furthermore, Phathom Pharmaceuticals estimated in 2024 that there are 115 million infected individuals in the United States alone, representing a substantial addressable market for diagnostic utilization.

Market Challenge

Significant economic and logistical barriers to deploying high-precision testing in developing nations constitute a major impediment to the growth of the Global Helicobacter Pylori Diagnostics Market. While these regions exhibit the highest density of bacterial colonization, the substantial costs of non-invasive modalities render them financially inaccessible for widespread screening. This pricing disparity effectively excludes a vast segment of the potential patient pool from the addressable market, as healthcare systems in low-resource settings prioritize acute care over preventative surveillance. Consequently, diagnostic manufacturers face diminished revenue realization in geographies that hold the highest volume of latent demand.

Moreover, the deficiency in laboratory infrastructure severely limits the scalability of accurate detection methods. Many diagnostic protocols require specialized equipment that is often unavailable in underfunded medical centers, forcing reliance on empiric treatment and stalling the adoption of modern technologies. The magnitude of this missed opportunity is significant given the persistent disease burden; according to the American Gastroenterological Association in 2024, the global prevalence of Helicobacter pylori infection among children and adolescents persists at 35.1%. This statistic confirms a continuous reservoir of infection that current market strategies fail to reach due to these logistical barriers.

Market Trends

The rise of Antimicrobial Susceptibility Testing capabilities is fundamentally altering the clinical approach to Helicobacter pylori management, driven by the escalating failure rates of traditional empiric therapies. With global antibiotic resistance reaching critical levels, healthcare providers are increasingly prioritizing diagnostic tools that can identify specific bacterial resistance profiles, particularly for clarithromycin and metronidazole, prior to prescribing treatment. This transition from simple detection to detailed susceptibility profiling is essential to prevent the administration of ineffective regimens and to steward antibiotic use. According to the National Institutes of Health in December 2024, primary resistance rates among children were reported at 35.3% for metronidazole and 32.6% for clarithromycin, underscoring the urgent market demand for diagnostics that provide comprehensive resistance data.

Concurrently, a shift toward Personalized Precision Medicine Diagnostics is gaining traction, leveraging genotypic insights to tailor eradication strategies for individual patients. This trend moves the market beyond binary positive/negative results, encouraging the adoption of molecular assays that guide the selection of the most efficacious first-line therapies based on the patient's specific bacterial strain. By integrating genotypic resistance testing into routine care, clinicians can significantly improve treatment outcomes compared to standard trial-and-error methods. According to Digestive Disease Week in May 2025, the implementation of genotypic resistance testing to guide first-line therapy increased eradication success rates to 93%, compared to just 77% with empiric therapy, validating the clinical and commercial value of precision diagnostics.

Key Market Players

  • Thermo Fisher Scientific inc.
  • Biohit Oyj
  • Quest Diagnostics Incorporated
  • Meridian Bioscience
  • Bio-Rad Laboratories
  • Alpha Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Coris BioConcept
  • Certest Biotec
  • Epitope Diagnostics, Inc

Report Scope

In this report, the Global Helicobacter Pylori Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Helicobacter Pylori Diagnostics Market, By Type

  • Instruments
  • Reagents
  • Services

Helicobacter Pylori Diagnostics Market, By Technology

  • Immunoassays
  • POC
  • Molecular Diagnostics

Helicobacter Pylori Diagnostics Market, By End user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Helicobacter Pylori Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Helicobacter Pylori Diagnostics Market.

Available Customizations:

Global Helicobacter Pylori Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Helicobacter Pylori Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Instruments, Reagents, Services)
    • 5.2.2. By Technology (Immunoassays, POC, Molecular Diagnostics)
    • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Helicobacter Pylori Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End user

7. Europe Helicobacter Pylori Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End user
    • 7.3.2. France Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End user

8. Asia Pacific Helicobacter Pylori Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End user
    • 8.3.2. India Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End user

9. Middle East & Africa Helicobacter Pylori Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End user

10. South America Helicobacter Pylori Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Helicobacter Pylori Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Helicobacter Pylori Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Helicobacter Pylori Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Helicobacter Pylori Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Biohit Oyj
  • 15.3. Quest Diagnostics Incorporated
  • 15.4. Meridian Bioscience
  • 15.5. Bio-Rad Laboratories
  • 15.6. Alpha Laboratories Ltd
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Coris BioConcept
  • 15.9. Certest Biotec
  • 15.10. Epitope Diagnostics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer